文献速递肝病

索磷布韦联合达拉他韦联合或不联合利巴韦林治疗551例基因4型丙型肝炎相关肝硬化患者

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
PubMed 文献 · Aliment Pharmacol Ther · 2018-01-03

这项多中心研究纳入551例基因4型丙型肝炎相关肝硬化患者,其中初治432例、经治119例,均接受索磷布韦(400 mg)联合达拉他韦(60 mg)每日一次,加用基于体重的利巴韦林治疗12周;当利巴韦林禁忌时疗程延长至24周。按意向性分析,初治肝硬化患者SVR12率为92%,经治患者为87%;总体病毒学失败42例(8%),最常见不良事件为贫血、乏力、头痛、瘙痒。

要点

  • 初治肝硬化患者SVR12率为92%,经治患者为87%(意向性分析)。
  • 总体病毒学失败42例(8%),其中无应答32例(6%)、复发10例(2%)。
  • 严重不良反应主要见于CTP-B级肝硬化患者,包括肝细胞癌和肝性脑病。

核心结论

  • 索磷布韦联合达拉他韦方案在真实世界大型队列中治疗基因4型丙型肝炎相关肝硬化显示有效性和安全性。

研究设计与样本

  • 多中心研究纳入551例基因4型丙型肝炎相关肝硬化患者,其中初治432例、经治119例。
  • 所有患者接受索磷布韦(400 mg)联合达拉他韦(60 mg)每日一次,加用基于体重的利巴韦林治疗12周;当利巴韦林禁忌时疗程延长至24周。

主要发现

  • 意向性分析显示,初治肝硬化患者SVR12率为92%,经治患者为87%。
  • 总体病毒学失败42例(8%),其中无应答32例(6%)、复发10例(2%)。
  • 意向性分析显示,病毒学失败患者中CTP-A级31例(7%)、CTP-B级11例(13.3%)。
  • 最常见不良事件为贫血、乏力、头痛、瘙痒。
  • 严重不良反应主要见于CTP-B级肝硬化患者,包括肝细胞癌和肝性脑病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials. AIM: To investigate the efficacy and safety of SOF/DCV for treatment of patients with hepatitis C-related liver cirrhosis genotype 4. METHODS: Multicentre study involving 551 patients with liver cirrhosis genotype 4; 432 naïve patients and 119 treatment-experienced patients. All patients received SOF (400 mg) and DCV (60 mg) daily in addition to weight-based ribavirin (RBV) for 12 weeks and when RBV is contraindicated the treatment duration was extended to 24 weeks. RESULTS: Sustained virological response at 12 weeks after end of treatment (SVR12) rate was 92% in naïve cirrhotic patients and 87% in previous treated patients (by ITT analysis). Virological failure was infrequent, occurring in 42 patients (8%) overall. Thirty-two (6%) were non responders; and 10 (2%) cases were relapsers, 31 patients (7%) were CTP-A and 11 (13.3%) patients were CTP-B (by ITT analysis). The most common adverse events were anaemia, fatigue, headache, pruritus. Serious side effects were recorded mainly in CTP-B cirrhotic patients including HCC and hepatic encephalopathy. CONCLUSIONS: The SOF/DCV combination therapy has proven efficacy and safety in treating patients with hepatitis C-related liver cirrhosis genotype 4 in a large cohort of patients in the real world.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. El-Khayat H, Fouad Y, Mohamed HI, et al. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018. PMID: 29314146. doi:10.1111/apt.14482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。